Close Window

Digital Look Email A Friend

ValiRx further extends letter of intent with TheoremRx

Published by Josh White on 31st December 2024

(Sharecast News) - ValiRx, a life science company specialising in early-stage cancer therapeutics and women's health, announced a further amendment to its letter of intent with TheoremRx regarding the proposed sub-license of VAL201 on Tuesday.

URL: http://www.digitallook.com/dl/news/story/34784027/...

Email this article to your friends
NOTE: These email addresses will be used to email the information on your behalf and will not be collected by Digital Look for any marketing purposes.